[Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients].
Eighty-two evaluable patients suffering from UTI were randomly treated with parenteral Aztreonam (1 g OD in cystitis and 1 g BID in pyelonephritis) or oral Norfloxacin (400 mg BID). Predisposing urological conditions were present in 75% and 78.5% respectively. Microbiological cultures at the end of treatment and at a follow-up visit after 4 weeks showed significantly better results among Aztreonam treated patients (microbiological cure: 97.5% vs 71.4%-p less than or equal to 0.005). Clinical cure was achieved in 97.5% and 71.4% respectively (p less than or equal to 0.001). A statistically significant difference was present only in patients treated for pyelonephritis (microbiological cure-AZT: 100%; NOR: 50%-p less than or equal to 0.0005) and not in those with cystitis (AZT: 95.0%; NOR: 83.3%). Side effects were rare in both treatments. Aztreonam seems to offer major advantages, when compared to Norfloxacin, in the treatment of UTI, especially when upper urinary tract is involved.
Puppo
P
P
Germinale
F
F
De Rose
A F
AF
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D001398:Aztreonam / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003556:Cystitis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007297:Inpatients; D008297:Male; D008875:Middle Aged; D009643:Norfloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D011704:Pyelonephritis / Q000188:drug therapy; D011897:Random Allocation; D012008:Recurrence; D014552:Urinary Tract Infections / Q000188:drug therapy*
D001398:Aztreonam; D009643:Norfloxacin
Aztreonam vs norfloxacina: studio comparativo nel trattamento delle infezioni delle vie urinarie in pazienti ambulatoriali ed ospedalizzati.